Beijing and Hong Kong – Paul Hastings LLP, a leading global law firm, announced today that it has advised Morgan Stanley Asia Limited and CLSA Capital Markets Limited as joint sponsors in the US$160 million global offering and Hong Kong Stock Exchange IPO and listing of Chinese vaccine company CanSino Biologics Inc (“CanSinoBIO”).
CanSinoBIO is the first vaccine company listed on the Hong Kong Stock Exchange and the seventh listing under Chapter 18A, the new chapter of the Listing Rules effective since April 2018 designed to attract early-stage biotech companies. Paul Hastings also advised on the Ascletis Pharma IPO, the first listing under Chapter 18A.
The Paul Hastings team was led by partners Nan Li and Zhaoyu Ren with associates Crystal Zhang, Stella Hu, China associates Berton Wang, Sean Ge, Vivi Song, and Xiaoxiao Liu.
At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.